Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 5:02 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Kiniksa Pharmaceuticals, Ltd. (KNSA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.67 | $38.00 | $28.00 | 27.02% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Kiniksa Pharmaceuticals, Ltd. comes to $32.67. The forecasts range from a low of $28.00 to a high of $38.00. The average price target represents an increase of 27.02% from the last closing price of $25.72.
Analyst Price Targets (6 )
Broker Rating
Kiniksa Pharmaceuticals, Ltd. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/KNSA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/23/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
5/3/2024 | Wells Fargo Securities | Eva Fortea-Verdejo | Not Available | Strong Buy |
4/24/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
3/29/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $32.67 |
LT Growth Rate | 150.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | -0.01 |